Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

In newly diagnosed GBM,

Optune was safely combined with TMZ

No late-emerging serious AEs were seen in the 5-year follow-up1

AE Chart AE Chart

No significant increase in serious AEs compared with TMZ alone1

  • The most common (≥10%) AEs involving Optune in combination with TMZ were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression2
  • A slightly higher incidence of grade 1/2 AEs was seen in some of the systems in the Optune + TMZ arm of the study. This is most likely a reflection of the longer duration of TMZ treatment in these patients3
  • The rate of grade 1/2 medical device site reaction was 52% for Optune + TMZ compared with 0% for TMZ alone1
  • Grade 3/4 AEs were well balanced between arms. None of the systemic grade 3/4 AEs were considered related to Optune by any of the investigators1
  • Mild-to-moderate skin irritation, the most common device-related side effect with Optune, was easily manageable, reversible, and did not result in treatment discontinuation1

AEs, adverse events; GBM, glioblastoma; TMZ, temozolomide.

References: 1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2­­3­­0­­6­­-­­2­­3­­1­­6. 2. Novocure Data on File OPT-103. 3. Optune Instructions For Use. Novocure 2016.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).